Mers-cov And Common Respiratory Pathogens Semi-quantitative And Quantitative Multiplex Nucleic Acid Detection System
Pathology · 21 CFR 866.4001
A Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and common respiratory pathogens qualitative, semi-quantitative or quantitative multiplex nucleic acid detection system is an in vitro diagnostic test for the detection, identification, and quantification of MERS-CoV and common respiratory pathogens associated nucleic acids in human clinical specimens. The test is indicated for individuals meeting specific MERS-CoV clinical and/or epidemiological criteria. It aids in the differential diagnosis of MERS-CoV infection in conjunction with other clinical, epidemiologic, and laboratory data, in accordance with the guidelines provided by the appropriate public health authorities.
Recent MDR events
7 adverse event reports on file
- FILMARRAY® PNEUMONIA PANEL PLUSMar 27, 2025DeathBiofire Diagnostics, Llc3002773840-2025-00018
- FILMARRAY® PNEUMONIA PANEL PLUSMar 13, 2025InjuryBiofire Diagnostics, Llc3002773840-2025-00015
- FILMARRAY® PNEUMONIA PANEL PLUSMar 13, 2025InjuryBiofire Diagnostics, Llc3002773840-2025-00014
- FILMARRAY® PNEUMONIA PANEL PLUSAug 29, 2024DeathBiofire Diagnostics, Llc3002773840-2024-00378
- FILMARRAY® PNEUMONIA PANEL PLUSAug 23, 2024InjuryBiofire Diagnostics, Llc3002773840-2024-00372
- FILMARRAY PNEUMONIA PANEL PLUSMay 25, 2022DeathBiofire Diagnostics, Llc3002773840-2022-00001
- BIOFIRE FILMARRAY V.1.7 RESPIRATORY PANELDec 20, 2019MalfunctionBiofire Diagnostics, Llc9503258
Event type breakdown
Most-reported manufacturers
Recalls
5 recall events for this product code
- BioFire Diagnostics, LLCOpen, ClassifiedApr 4, 2025
FilmArra Pneumonia Panel plus (Pneumoplus), REF: RFIT-LBL-0374
Increased risk of control failures and false negative test results with multiplexed nucleic acid test.
Z-1518-2025 · View FDA record ↗ - BioFire Diagnostics, LLCOpen, ClassifiedAug 16, 2024
BIOFIRE FILMARRAY Pneumonia Panel, REF: RFIT-ASY-0144
Pneumonia panels have an increased risk of control failures due to an issue in the manufacturing process, which could lead to delayed results for the customer.
Z-2682-2024 · View FDA record ↗ - BioFire Diagnostics, LLCOpen, ClassifiedAug 16, 2024
BIOFIRE FILMARRAY Pneumonia Panel plus, REF: RFIT-ASY-0143
Pneumonia panels have an increased risk of control failures due to an issue in the manufacturing process, which could lead to delayed results for the customer.
Z-2683-2024 · View FDA record ↗ - BioFire Diagnostics, LLCOpen, ClassifiedFeb 6, 2024
FilmArray Pneumonia Panel Plus (Pneumoplus), REF: RFIT-ASY-0143, CED 2797, IVD, Rx Only (30 test kit)
Their is a potential for false positive results when using Pneumonia panel.
Z-0993-2024 · View FDA record ↗ - BioFire Diagnostics, LLCTerminatedUnknown
FilmArray Pneumonia Panel plus (Pneumoplus)
Due to real-time stability study failures resulting in increase rate of false negative results between the 6 to 12 month expiry time-frame.
Z-2040-2021 · View FDA record ↗
Registered firms
3 firms currently registered for this product code
510(k) clearances
3 clearances for this product code
- Biofire Diagnostics, LLC (Biomerieux)Nov 6, 2024
K243222 · BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE® FILMARRAY® Pneumonia Panel plus (BIOFIRE Pneumonia Panel plus)
- Biofire Diagnostics, LLCOct 27, 2022
K222601 · FilmArray Pneumonia Panel plus
- Biofire Diagnostics, LLCNov 15, 2018
K181324 · FilmArray Pneumonia Panel plus